- Conditions
- Cutaneous T-Cell Lymphoma/Mycosis Fungoides
- Interventions
- Hypericin, Mechlorethamine Topical Gel
- Drug
- Lead sponsor
- Soligenix
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Fairport, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–11
of 11
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Chronic Gastrointestinal Graft vs Host Disease
- Interventions
- orBec, Placebo
- Drug
- Lead sponsor
- Soligenix
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 3
- States / cities
- Hackensack, New Jersey • Buffalo, New York • Nashville, Tennessee
- Conditions
- Cutaneous T-Cell Lymphoma/Mycosis Fungoides
- Interventions
- Hypericin
- Drug
- Lead sponsor
- Soligenix
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Fairport, New York
- Conditions
- CTCL/ Mycosis Fungoides, CTCL, Mycosis Fungoides, Cutaneous T Cell Lymphoma
- Interventions
- Hypericin, Placebo
- Drug
- Lead sponsor
- Soligenix
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 17
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • San Diego, California + 14 more
- Conditions
- Cutaneous T-Cell Lymphoma
- Interventions
- SGX301 (synthetic hypericin), Placebo
- Drug
- Lead sponsor
- Soligenix
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 169 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 33
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 27 more
- Conditions
- Oral Mucositis
- Interventions
- SGX942, Placebo
- Drug
- Lead sponsor
- Soligenix
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 111 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Lexington, Kentucky
- Conditions
- Squamous Cell Carcinoma of the Oral Cavity and Oropharynx, Oral Mucositis
- Interventions
- SGX942, Placebo
- Drug
- Lead sponsor
- Soligenix
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 266 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 32
- States / cities
- Tucson, Arizona • Loma Linda, California • Pomona, California + 29 more
- Conditions
- Acute Gastrointestinal Graft vs Host Disease
- Interventions
- oral beclomethasone 17,21-dipropionate, Placebo
- Drug
- Lead sponsor
- Soligenix
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 3
- States / cities
- Buffalo, New York • Durham, North Carolina • Seattle, Washington
- Conditions
- Cutaneous T Cell Lymphoma, Mycosis Fungoides
- Interventions
- Hypericin, Visible Light
- Drug · Other
- Lead sponsor
- Ellen Kim, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Enteritis
- Interventions
- SGX201 (delayed release beclomethasone 17,21-dipropionate)
- Drug
- Lead sponsor
- Soligenix
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Boston, Massachusetts
- Conditions
- Psoriasis, Plaque Psoriasis, Psoriasis Vulgaris
- Interventions
- Hypericin
- Drug
- Lead sponsor
- Soligenix
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- San Diego, California